NCT03344159View on ClinicalTrials.gov

Spironolactone Therapy in Chronic Stable Right HF Trial

PHASE4CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

April 1, 2018

Primary Completion Date

August 30, 2022

Study Completion Date

May 1, 2024

Conditions
Chronic Right-Sided Heart FailurePulmonary Arterial HypertensionPulmonary Hypertension, Primary, 2Pulmonary Hypertension, Primary, 3Pulmonary Hypertension, Primary, 4Cardiomyopathy Right Ventricular
Interventions
DRUG

Spironolactone

Spironolactone 12.5mg daily up to a maximum dose of 50 mg daily if tolerated for a total duration of 12 weeks.

DRUG

Placebo

Placebo daily for a total of duration of 12 weeks

RADIATION

PET/CT Scan: Two PET scans using 1. C-11 HED and 2. N-13 Ammonia or rubidium-82

At baseline and 12 weeks, all participants will undergo rest perfusion PET imaging according to standard protocols with either 82-Rb or N-13 NH3, followed by C-11 HED PET.

DIAGNOSTIC_TEST

Cardiac MRI (Gadolinium enhanced)

At baseline and 12 weeks all participants will undergo cMR to assess RV function and structure. We will acquire precontrast T2 and native T1 maps, and post gadolinium T1 maps.

Trial Locations (1)

K1Y4W7

University of Ottawa Heart Institute, Ottawa

All Listed Sponsors
lead

Ottawa Heart Institute Research Corporation

OTHER

NCT03344159 - Spironolactone Therapy in Chronic Stable Right HF Trial | Biotech Hunter | Biotech Hunter